A

Aurinia Pharmaceuticals
D

AUPH

7.92000
USD
0.10
(1.21%)
مغلق
حجم التداول
48,552
الربح لكل سهم
1
العائد الربحي
-
P/E
-53
حجم السوق
1,133,979,810
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ACAD
    -0.350
    (-1.73%)
    19.940 USD
    B
    BLUE
    -2.93000
    (-41.68%)
    4.10000 USD
    B
    BMRN
    -0.525
    (-0.76%)
    68.215 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    D
    DVAX
    0.000
    (0.00%)
    13.335 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    L
    LGND
    -1.350
    (-1.11%)
    120.680 USD
    R
    RARE
    -1.920
    (-4.31%)
    42.590 USD
    S
    SRPT
    -2.010
    (-1.86%)
    106.280 USD
    المزيد
الأخبار
المقالات

العنوان: Aurinia Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.